Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00623194
Recruitment Status : Completed
First Posted : February 25, 2008
Results First Posted : January 24, 2011
Last Update Posted : November 28, 2016
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This trial is conducted in Europe. The aim of this research is to assess the safety of continuous treatment with insulin detemir following participation in trial NN304-1689 (NCT00435019) on antibody development.

Condition or disease Intervention/treatment Phase
Diabetes Diabetes Mellitus, Type 1 Drug: insulin detemir Drug: insulin aspart Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 146 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 52-Week, Multinational, Multi-Centre, Open-Labelled Extension Trial of Insulin Detemir in Children and Adolescents 3-17 Years With Type 1 Diabetes on a Basal-Bolus Regimen With Insulin Aspart as Bolus Insulin
Study Start Date : February 2008
Actual Primary Completion Date : September 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: insulin detemir
Insulin detemir up to twice daily plus insulin aspart at larger meals, doses are adjusted individually (treatment up to 104 weeks)
 Drug: insulin detemir
Treat-to-target dose titration scheme (individually adjusted), injection s.c. (under the skin), once or twice daily.

Drug: insulin aspart
Treat-to target dose titration scheme (individually adjusted), injection s.c. (under the skin), at larger meals.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Insulin Detemir-insulin Aspart Cross-reacting Antibodies [ Time Frame: week 0, 52 and 104 ]
    Estimated amount of bound antibodies in percent of total antibodies. The primary analysis of cross-reacting antibodies included results from blood samples taken before insulin detemir and less than 3 hours after insulin aspart injection. In addition, an analysis was done including results from samples taken before insulin detemir and less than 2.5 hours after insulin aspart injection.


Secondary Outcome Measures :
  1. Development of Insulin Detemir Specific Antibodies and Insulin Aspart Specific Antibodies [ Time Frame: At 0, 52 and 104 weeks ]
    Amount of Insulin Detemir and Insulin Aspart specific antibodies in percent of total antibodies after 0, 52 and 104 weeks.

  2. Glycosylated Haemoglobin A1c (HbA1c) [ Time Frame: At 104 weeks ]
    Glycosylated Haemoglobin A1c (HbA1c) measured after 104 weeks.

  3. Fasting Plasma Glucose Values [ Time Frame: At 104 weeks ]
    FPG (Fasting Plasma Glucose) values after 104 weeks.

  4. Hypoglycaemic Episodes [ Time Frame: Weeks 0-104 ]

    Mild: signs/symptoms but able to treat him/herself. Moderate: signs/symptoms not able to treat him/herself. Responds to oral treatment.

    Severe: signs/symptoms and unable to treat him/herself. semiconscious/unconscious/in coma +/- convulsion and may require parenteral treatment.


  5. BMI (Body Mass Index) [ Time Frame: At 104 weeks ]
    BMI (Body Mass Index) after 104 weeks.

  6. SD-score (Z-score) for Body Weight [ Time Frame: At 104 weeks ]
    Standard deviation-score (SD-score) after 104 weeks. The SD-score for weight was calculated based on a British reference population from 1990. To estimate the growth of children, standardised mean weight values were calculated for each month of age and for each sex. Thus, a child with a weight equal to the mean value for its age and sex has an SD score of 0, while a child with a weight 2 SDs above the mean value for its age and sex has an SD score of +2.

  7. Diabetic Ketoacidosis [ Time Frame: At 104 weeks ]
    Diabetic ketoacidosis requiring hospitalisation

  8. Insulin Dose [ Time Frame: At 104 weeks ]
    Daily insulin doses (basal (Insulin Detemir) and bolus (Insulin Aspart)) at week 104.

  9. Laboratory Values: Albumin Serum and Total Protein Serum (g/dL) [ Time Frame: At 104 weeks ]
    Albumin Serum and Total Protein Serum after 104 weeks.

  10. Laboratory Values: Creatine Serum Umol/L [ Time Frame: At 104 weeks ]
    Creatine serum after 104 weeks.

  11. Laboratory Values: Sodium Serum, Potassium Serum and Haemoglobin (mmol/L) [ Time Frame: At 104 weeks ]
    Sodium Serum, Potassium Serum and Haemoglobin after 104 weeks.

  12. Laboratory Values: Alkaline Phosphatase Serum, Alanine Aminotransferase Serum and Lactate Dehydrogenase Serum (U/L) [ Time Frame: At 104 weeks ]
    Alkaline phosphatase serum, Alanine Aminotransferase serum and Lactate Dehydrogenase serum after 104 weeks.

  13. Laboratory Values: Leukocytes and Thrombocytes [ Time Frame: At 104 weeks ]
    Leukocytes and Thrombocytes after 104 weeks.

  14. Fundoscopy/Fundus Photography [ Time Frame: at 52 weeks and at 104 weeks ]

    Fundoscopy after 104 weeks. Abn. CS = Abnormal, clinically significant Abn. NCS = Abnormal, Not clinically significant

    Abn. CS = Abnormal, clinically significant Abn. NCS = Abnormal, Not clinically significant


  15. Vital Signs: Blood Pressure [ Time Frame: At 104 weeks ]
    Blood pressure (Systolic and Diastolic) after 104 weeks.

  16. Vital Signs: Pulse [ Time Frame: At 104 weeks ]
    Pulse at week 104


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Informed Consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject). The parents or legal representative of the subject must sign and date the Informed Consent Form.
  • Finalised 52 weeks of treatment with insulin detemir in trial NN304-1689.
  • Fertile females (girls who have had their first menstrual period) must use adequate contraception (barrier methods, contraceptive pills or intrauterine device (IUD)) if there is any risk of pregnancy in the opinion of the Investigator. For Denmark and France only contraceptive pills or intrauterine device are considered as adequate contraceptive methods.

Exclusion Criteria:

  • Significant concomitant disease such as endocrine, hepatic, renal, cardiac, respiratory, neurological, gastrointestinal, malignant or pancreatic diseases as judged by the Investigator.
  • Pregnant or the intention of becoming pregnant.
  • Previous participation in this trial (defined as enrolment).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00623194


Locations
Layout table for location information
Bulgaria
Novo Nordisk Investigational Site
Pleven, Bulgaria, 5800
Novo Nordisk Investigational Site
Sofia, Bulgaria, 1606
Novo Nordisk Investigational Site
Varna, Bulgaria, 9010
Czech Republic
Novo Nordisk Investigational Site
Olomouc, Czech Republic, 77520
Novo Nordisk Investigational Site
Pardubice, Czech Republic, 53203
Novo Nordisk Investigational Site
Prague 5, Czech Republic, 15018
Denmark
Novo Nordisk Investigational Site
Glostrup, Denmark, 2600
Novo Nordisk Investigational Site
Kolding, Denmark, 6000
Novo Nordisk Investigational Site
Odense, Denmark, 5000
Finland
Novo Nordisk Investigational Site
Helsinki, Finland, 00029
Novo Nordisk Investigational Site
Oulu, Finland, 90029
Novo Nordisk Investigational Site
Seinäjoki, Finland, 60220
Novo Nordisk Investigational Site
Turku, Finland, 20100
France
Novo Nordisk Investigational Site
Paris, France, 75015
Novo Nordisk Investigational Site
Toulouse, France, 31059
Hungary
Novo Nordisk Investigational Site
Budapest, Hungary, 1083
Novo Nordisk Investigational Site
Miskolc, Hungary, 3501
Macedonia, The Former Yugoslav Republic of
Novo Nordisk Investigational Site
Skopje, Macedonia, The Former Yugoslav Republic of, 1000
Poland
Novo Nordisk Investigational Site
Gdansk, Poland, 80-211
Novo Nordisk Investigational Site
Kielce, Poland, 25-734
Novo Nordisk Investigational Site
Warszawa, Poland, 01-184
Russian Federation
Novo Nordisk Investigational Site
Moscow, Russian Federation, 117036
Novo Nordisk Investigational Site
Moscow, Russian Federation, 119049
Novo Nordisk Investigational Site
Moscow, Russian Federation, 125373
Novo Nordisk Investigational Site
Saint-Petersburg, Russian Federation, 193144
Turkey
Novo Nordisk Investigational Site
Altunizade-Istanbul, Turkey, 34662
Novo Nordisk Investigational Site
Antalya, Turkey, 07059
Novo Nordisk Investigational Site
Istanbul, Turkey, 34093
Novo Nordisk Investigational Site
Izmir, Turkey, 35340
United Kingdom
Novo Nordisk Investigational Site
Aberdeen, United Kingdom, AB25 2ZG
Novo Nordisk Investigational Site
Dundee, United Kingdom, DD1 9SY
Novo Nordisk Investigational Site
Norfolk, United Kingdom, NR4 7UY
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Layout table for investigator information
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications:

Layout table for additonal information
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT00623194    
Other Study ID Numbers: NN304-1690
2006-002478-23 ( EudraCT Number )
First Posted: February 25, 2008    Key Record Dates
Results First Posted: January 24, 2011
Last Update Posted: November 28, 2016
Last Verified: October 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
 Insulin
Insulin, Globin Zinc
Insulin Aspart
Insulin Detemir
Hypoglycemic Agents
Physiological Effects of Drugs